Sanofi recalled EpiPen's primary branded rival, Auvi-Q, on Wednesday because of concerns about dosing accuracy.
To see if your Auvi-Q units are included in the recall, you can find a link to the product recall page in the Seen on 7 section of our website. Lantus also faces competition from a less expensive rival that could go on sale in the USA late next year, after Sanofi settled a lawsuit that allows rivals Eli Lilly and Co. and German drugmaker Boehringer Ingelheim GmbH to sell their version starting December 15, 2016.
The French drug and vaccine maker said it has received 26 reports of malfunctions with the injectors.
If someone was experiencing a serious allergic reaction and did not receive the correct dose, there could have significant health consequences, including death, according to the FDA.
In response to the recall, Mylan, which makes the EpiPen epinephrine auto-injector, issued a statement noting that its products are not affected by the recall and are now available for patients who need an auto-injecting epinephrine in case of anaphylaxis.
Auvi-Q is packaged with two active devices and one trainer device in a corrugate' box and was distributed throughout the United States through wholesalers, pharmacies and hospitals. The Paris-based company said it has kept the Food and Drug Administration abreast of the recall. The agency approved Auvi-Q in August 2012.